News

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses On Their Investment In Hims & Hers Health, Inc. Of Class Action Lawsuit And Upcoming Deadlines - HIMS
On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over“Deceptive” Marketing Of Wegovy Hagens Berman
The lawsuits follow an announcement by Novo Nordisk that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers' sales and“deceptive” marketing of the weight ...
BioPharma Dive42m
Private equity firms back PCI Pharma in strategic bet on drug production
The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.